OncoCyte
- Country
- Ownership
- -
- Employees
- 46
- Market Cap
- -
- Introduction
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.
Clinical Trials
1
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Predictive Assay for Decision Making in Adjuvant Therapy
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: AdjuvantOther: Observation
- First Posted Date
- 2021-09-02
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- OncoCyte
- Target Recruit Count
- 55
- Registration Number
- NCT05032352
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸George Washington Medical Faculty Associates, Washington, District of Columbia, United States
News
Oncocyte Advances Toward Clinical Trial for Organ Transplant Rejection Test Kit
Oncocyte has received central IRB approval for its clinical trial design and expects to enroll three of the top 10 U.S. transplant centers, representing nearly 10% of annual U.S. transplant volume.
Oncocyte's Blood-Based Transplant Rejection Assay Shows Long-Term Clinical Validity in 13-Year Study
Oncocyte's proprietary blood-based assay demonstrated clinical validity in monitoring kidney transplant patients for up to 13.7 years post-transplant, validating its utility for long-term patient management.
Oncocyte Advances GraftAssure Adoption and FDA Submission for Transplant Monitoring
Oncocyte is expanding the reach of its GraftAssure test, securing agreements with transplant centers representing 9% of German and 2% of U.S. transplant volumes.
DetermaIO Gene Test Predicts Atezolizumab Benefit in Triple-Negative Breast Cancer
DetermaIO, a 27-gene expression test, can identify TNBC patients likely to benefit from atezolizumab added to chemotherapy, improving pathologic complete response (pCR) rates.